{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:55:02Z","timestamp":1767135302596,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd012040.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000}}],"reference-count":80,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012040.pub3","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T07:35:06Z","timestamp":1677828906000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Aisha A","family":"Aslam","sequence":"additional","affiliation":[{"name":"The Children\u2019s Hospital; Royal London Hospital; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian P","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health; University of Liverpool; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health; University of Liverpool; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"10.1002\/14651858.CD012040.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1569-1993(13)60205-2","article-title":"The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease","volume":"12(Suppl 1)","author":"Ajayi","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(16)30133-3","article-title":"Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range","volume":"15(Suppl 1)","author":"Davies","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S45","key":"10.1002\/14651858.CD012040.pub3-BIB0003|cit3","first-page":"273","article-title":"Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin","volume":"51","author":"De Boeck","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(16)30132-1","article-title":"Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin","volume":"15(Suppl 1)","author":"De Boeck","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0005|cit5","first-page":"312","article-title":"Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF)","volume":"49(Suppl 38)","author":"DeBoeck","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0006|cit6","unstructured":"A phase 3 efficacy and safety study of PTC124 AS an oral treatment for nonsense-mutation-mediated cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2008-003924-52-FR"},{"issue":"7","key":"10.1002\/14651858.CD012040.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S1569-1993(16)30502-1","article-title":"Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study","volume":"15(Suppl 1)","author":"Kerem","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0009|cit9","first-page":"312","article-title":"Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease","volume":"47(Suppl 35)","author":"Kerem","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1569-1993(11)60084-2","article-title":"Phase 3 study of ataluren (PTC124\u00ae) in nonsense mutation cystic fibrosis (nmCF): baseline data","volume":"10(Suppl 1)","author":"Kerem","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0011|cit11","first-page":"314","article-title":"Phase 3 study of Ataluren (PTC124\u00ae) in nonsense mutation cystic fibrosis (NMCF): demographic & other baseline data","volume":"45(Suppl 33)","author":"Kerem","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S1569-1993(14)60230-7","article-title":"The effect of Pseudomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis","volume":"13(Suppl 2)","author":"Kerem","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S1569-1993(13)60044-2","article-title":"Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF)","volume":"12(Suppl 1)","author":"Kerem","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0014|cit14","first-page":"311","article-title":"Sustained improvement in lung function in an open-label extension study of ataluren in patients with nonsense mutation cystic fibrosis","volume":"49(Suppl 38)","author":"Konstan","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0015|cit15","first-page":"295","article-title":"Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis","volume":"46(Suppl 34)","author":"Konstan","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0016|cit16","first-page":"298","article-title":"Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis","volume":"48(Suppl 36)","author":"Konstan","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0017|cit17","unstructured":"Study of ataluren (PTC124\u2122) in cystic fibrosis clinicaltrials.gov\/show\/NCT00803205"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0018|cit18","first-page":"290","article-title":"Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF)","volume":"47(Suppl 35)","author":"Rowe","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0019|cit19","first-page":"279","article-title":"The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis","volume":"48(Suppl 36)","author":"Rowe","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"PA4869","DOI":"10.1183\/13993003.congress-2016.PA4869","article-title":"Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: evaluation of exacerbations and lung function","volume":"48(Suppl 60)","author":"Sermet-Gaudelus","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/S1569-1993(17)30574-X","article-title":"Changes in chest CT abnormalities of 92 nonsense-mutation CF patients over 48 weeks","volume":"16(Suppl 1)","author":"Taybi","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD012040.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e0240898","DOI":"10.1371\/journal.pone.0240898","article-title":"Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: lessons learned from the first ataluren phase 3 study","volume":"15","author":"Tiddens","year":"2020","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S1569-1993(17)30303-X","article-title":"Baseline chest CT abnormalities of 202 nonsense-mutation CF patients participating in the ataluren phase 3 trial","volume":"16(Suppl 1)","author":"Tiddens","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0024|cit24","unstructured":"Confirmatory study of ataluren in patients with Cystic Fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(17)30233-3","article-title":"Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF)","volume":"16 (Suppl 1)","author":"Konstan","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD012040.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jcf.2020.01.007","article-title":"Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)","volume":"19","author":"Konstan","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0027|cit27","first-page":"280","article-title":"Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy","volume":"51(Suppl 45)","author":"McIntosh","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0028|cit28","unstructured":"A phase 3 efficacy and safety study of ataluren (PTC124\u00ae) in patients with nonsense mutation cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT02139306"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0030|cit30","first-page":"294","article-title":"PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis","volume":"43(Suppl 31)","author":"Kerem","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(08)60085-5","article-title":"PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF","volume":"7(Suppl 2)","author":"Wilschanski","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0033|cit33","unstructured":"A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00234663"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0034|cit34","unstructured":"Safety and efficacy of ataluren (PTC124) for cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00237380"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0035|cit35","unstructured":"A phase 2b extension study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00351078"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0036|cit36","unstructured":"Application of functional electrophysiological tests to evaluate pharmacological treatments in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00376428"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0037|cit37","unstructured":"A phase 3 extension study of ataluren (PTC124\u00ae) in subjects with nonsense-mutation-mediated cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01140451"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0038|cit38","unstructured":"An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124\u00ae) clinicaltrials.gov\/ct2\/show\/NCT02107859"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0039|cit39","unstructured":"Extension study of ataluren in participants with nonsense mutation cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT02456103"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0040|cit40","unstructured":"An open label study to investigate the role of ivacaftor for the treatment of cystic fibrosis in combination with ataluren (PTC124) in cystic fibrosis patients using ataluren for nonsense mutations clinicaltrials.gov\/ct2\/show\/NCT03256799"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0041|cit41","unstructured":"An open label N of 1 study to evaluate the study and efficacy of long-term treatment with ivacaftor in combination with ataluren (PTC124) in subjects with nonsense mutation cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT03256968"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0042|cit42","unstructured":"Novel therapeutic approaches for treatment of CF patients with W1282X premature termination codon mutations clinicaltrials.gov\/ct2\/show\/NCT03624101"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0043|cit43","unstructured":"Optimization of correcting molecules of nonsense mutations in epithelial cells of the upper airways of patients with cystic fibrosis with nonsense mutations in the CFTR gene clinicaltrials.gov\/ct2\/show\/NCT03670472"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0044|cit44","unstructured":"A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele clinicaltrials.gov\/ct2\/show\/NCT04126473"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0045|cit45","unstructured":"A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele clinicaltrials.gov\/ct2\/show\/NCT04135495"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0046|cit46","first-page":"263","article-title":"Effects of gentamicin on ion transport, mRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study","volume":"34, Issue S24","author":"Pradal","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0047|cit47","unstructured":"Romano L Casciaro R Vanini P Zegarra-Moran O Negro I Minuto N Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 11"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0048|cit48","first-page":"250","article-title":"Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense-mutations","volume":"30, Issue S20","author":"Romano","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0049|cit49","unstructured":"A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-000724-40-BE"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0050|cit50","unstructured":"A study of ataluren in pediatric participants with cystic fibrosis clinicaltrials.gov\/show\/NCT00458341"},{"issue":"10","key":"10.1002\/14651858.CD012040.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0052|cit52","first-page":"313","article-title":"Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124","volume":"43(Suppl 31)","author":"Sermet-Gaudelus","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(08)60084-3","article-title":"PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF","volume":"7(Suppl 2)","author":"Sermet-Gaudelus","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0054|cit54","first-page":"244","article-title":"Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: A double-blind placebo controlled trial","volume":"30, Issue S20","author":"Wilschanski","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012040.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"A582","DOI":"10.1016\/S0016-5085(03)82949-9","article-title":"Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: A double blind placebo controlled trial","volume":"124","author":"Wilschanski","year":"2003","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD012040.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012040.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"231\u201340","DOI":"10.1016\/j.molmed.2007.05.001","article-title":"Cystic fibrosis: A disease of vulnerability to airway surface dehydration","volume":"13","author":"Boucher","year":"2007","journal-title":"Trends in Molecular Medicine"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0058|cit58","unstructured":"Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto Cystic fibrosis mutation database www.genet.sickkids.on.ca\/StatisticsPage.html"},{"issue":"7","key":"10.1002\/14651858.CD012040.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012040.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch10"},{"issue":"12","key":"10.1002\/14651858.CD012040.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"European Journal of Human Genetics"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0063|cit63","volume-title":"Building Biotechnology","author":"Friedman","year":"2014"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012040.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0066|cit66","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0067|cit67","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD012040.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012040.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/gte.1997.1.35","article-title":"Cystic fibrosis in Jews: frequency and mutation distribution","volume":"1","author":"Kerem","year":"1997","journal-title":"Genetic Testing"},{"issue":"6","key":"10.1002\/14651858.CD012040.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pbio.1001593","article-title":"A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays","volume":"11","author":"McElroy","year":"2013","journal-title":"PLoS Biology"},{"issue":"5","key":"10.1002\/14651858.CD012040.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.130.5.1441","article-title":"CFTR genotype as a predictor of prognosis in cystic fibrosis","volume":"130","author":"McKone","year":"2006","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD012040.pub3-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1042\/BST0381615","article-title":"Cutting the nonsense: the degradation of PTC-containing mRNAs","volume":"38","author":"Nicholson","year":"2010","journal-title":"Biochemical Society Transactions"},{"issue":"6","key":"10.1002\/14651858.CD012040.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD012040.pub3-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009841.pub3","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","author":"Skilton","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD012040.pub3-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966.pub3","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","author":"Southern","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0076|cit76","unstructured":"CF Trust UK Cystic fibrosis our focus. UK cystic fibrosis registry annual data report 2013 www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/2014%20Registry%20Annual%20Data%20Report%20SUMMARY.pdf"},{"issue":"7140","key":"10.1002\/14651858.CD012040.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1002\/14651858.CD012040.pub3-BIB0078|cit78","first-page":"5121\u201388","volume-title":"The Metabolic and Molecular Basis of Inherited Diseases","author":"Welsh","year":"2001"},{"issue":"15","key":"10.1002\/14651858.CD012040.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012040.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012040.pub2","article-title":"Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis","author":"Aslam","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T22:38:34Z","timestamp":1714948714000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012040.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012040.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}